Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations

SIMPLE SUMMARY: Patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor gene (EGFR) Exon 20 insertion mutations (Exon20ins) used to have poor outcomes after the failure of platinum-based therapies. Amivantamab, a drug that targets two proteins involved in NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Christopoulos, Petros, Girard, Nicolas, Proto, Claudia, Soares, Marta, Lopez, Pilar Garrido, van der Wekken, Anthonie J., Popat, Sanjay, Diels, Joris, Schioppa, Claudio A., Sermon, Jan, Rahhali, Nora, Pick-Lauer, Corinna, Adamczyk, Agnieszka, Penton, James, Wislez, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670157/
https://www.ncbi.nlm.nih.gov/pubmed/38001589
http://dx.doi.org/10.3390/cancers15225326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670157/
https://www.ncbi.nlm.nih.gov/pubmed/38001589
http://dx.doi.org/10.3390/cancers15225326

Ejemplares similares